ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

ClinicalTrials.gov ID: NCT06780449

Public ClinicalTrials.gov record NCT06780449. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Long-term Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Placebo in Participants With Obesity

Study identification

NCT ID
NCT06780449
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
400 participants

Conditions and interventions

Conditions

Interventions

  • Cagrilintide Drug
  • Placebo cagrilintide Drug
  • Placebo semaglutide Drug
  • Semaglutide Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 9, 2025
Primary completion
Aug 27, 2028
Completion
Oct 30, 2028
Last update posted
Jan 19, 2026

2025 – 2028

United States locations

U.S. sites
10
U.S. states
9
U.S. cities
10
Facility City State ZIP Site status
Valley Clinical Trials Covina California 91723
Diablo Clinical Research, Inc. Walnut Creek California 94598
Yale University School Of Medicine New Haven Connecticut 06519
East West Medical Research Institute_Honolulu Honolulu Hawaii 96814
L-MARC Research Center Louisville Kentucky 40213
StudyMetrix Research LLC City of Saint Peters Missouri 63303
Spartanburg Medical Research Spartanburg South Carolina 29303
Holston Medical Group_Bristol Bristol Tennessee 37620
North Texas Endocrine Center Dallas Texas 75231
Washington Cntr Weight Mgmt Arlington Virginia 22206

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06780449, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 19, 2026 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06780449 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →